Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.55 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 3/20 | 0.52 |
| ▸ | CTSL | P07711 | 2/20 | 0.52 |
| ▸ | CTSB | P07858 | 2/20 | 0.52 |
| ▸ | AKT1 | P31749 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12894955 | 0.91 | HDAC3 (0.51) | HDAC3HDAC1HDAC2NCOR2CTSS | |
| SCHEMBL13021076 | 0.91 | CTSL (0.54) | HDAC3HDAC1HDAC2NCOR2CTSS | |
| SCHEMBL2897902 | 0.87 | HDAC3 (0.46) | HDAC3HDAC1HDAC2NCOR2CTSS | |
| SCHEMBL3858652 | 0.87 | HDAC3 (0.46) | HDAC3HDAC1HDAC2NCOR2CTSS | |
| SCHEMBL13021069 | 0.87 | CTSL (0.50) | HDAC3HDAC1HDAC2NCOR2CTSS | |
| SCHEMBL13021079 | 0.87 | CTSL (0.50) | HDAC3HDAC1HDAC2NCOR2CTSS | |
| SCHEMBL7594665 | 0.86 | HDAC3 (0.44) | HDAC3HDAC1HDAC2NCOR2CTSS | |
| SCHEMBL23288368 | 0.86 | LMNA (0.60) | HDAC3HDAC1HDAC2NCOR2CTSS | |
| SCHEMBL13021085 | 0.86 | CTSL (0.49) | HDAC3HDAC1HDAC2NCOR2CTSS | |
| SCHEMBL4278729 | 0.85 | HDAC3 (0.54) | HDAC3HDAC1HDAC2NCOR2CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4698170-A1 | GLYCINAMIDE DERIVATIVES FOR USE IN THE TREATMENT OF SALMONELLOSIS | Eberhard-Karls-Universität Tübingen (DE) | 2026-02-25 | — | — | EP | disclosed |
| WO-2025202493-A1 | ANTIMICROBIAL PEPTOID TERPOLYMERS, PREPARATIONS AND USES THEREOF | VIKYNG AI (FR) | 2025-10-02 | — | — | WO | disclosed |
| WO-2025088200-A2 | ACID PHOSPHATASE 3 LIGANDS FOR TARGETED DELIVERY APPLICATIONS | PHILOCHEM AG (CH) | 2025-05-01 | — | — | WO | disclosed |
| WO-2024218333-A1 | GLYCINAMIDE DERIVATIVES FOR USE IN THE TREATMENT OF SALMONELLOSIS | EBERHARD KARLS UNIVERSITÄT TÜBINGEN MEDIZINISCHE FAKULTÄT (DE) | 2024-10-24 | — | — | WO | disclosed |
| US-20240189486-A1 | ANTIMICROBIAL CATIONIC PEPTOID AND N-SUBTITUTED PEPTIDIC COPOLYMERS, PREPARATION AND USES THEREOF | UNIVERSITÉ DE BORDEAUX (FR) | 2024-06-13 | — | — | US | disclosed |
| EP-4294821-A1 | ANTIMICROBIAL CATIONIC PEPTOID AND N-SUBTITUTED PEPTIDIC COPOLYMERS, PREPARATION AND USES THEREOF | UNIVERSITE DE BORDEAUX (FR) | 2023-12-27 | — | — | EP | disclosed |
| CN-115368261-A | Synthesis method of N-allyl-N-benzyl-2- (benzylamino) acetamide | 武汉理工大学 | 2022-11-22 | — | — | CN | disclosed |
| WO-2022175319-A1 | ANTIMICROBIAL CATIONIC PEPTOID AND N-SUBTITUTED PEPTIDIC COPOLYMERS, PREPARATION AND USES THEREOF | Universite de Bordeaux (FR) | 2022-08-25 | — | — | WO | disclosed |
| EP-4047012-A1 | ANTIMICROBIAL CATIONIC PEPTOID AND N-SUBTITUTED PEPTIDIC COPOLYMERS, PREPARATION AND USES THEREOF | Université de Bordeaux (FR) | 2022-08-24 | — | — | EP | disclosed |
| US-11389464-B2 | Arginase inhibitors as therapeutics | MARS, INCORPORATED (US) | 2022-07-19 | — | — | US | disclosed |
| EP-0970075-A1 | PYRIMIDINONE-1,3-OXATHIOLANE DERIVATIVES WITH ANTIVIRAL ACTIVITY | ZAMBON GROUP S.p.A. (IT) | 2000-01-12 | — | — | EP | disclosed |
| EP-0783318-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 1999-10-20 | — | — | EP | disclosed |
| EP-0871619-A1 | PHENYL THIAZOLE DERIVATIVES WITH ANTI HERPES VIRUS PROPERTIES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 1998-10-21 | — | — | EP | disclosed |
| WO-1998043972-A1 | PYRIMIDINONE-1,3-OXATHIOLANE DERIVATIVES WITH ANTIVIRAL ACTIVITY | ZAMBON GROUP S.P.A. (IT) | 1998-10-08 | — | — | WO | disclosed |
| US-5700779-A | ALLEVIATING PAIN, ASTHMA, INFLAMMATION, CEREBRAL EDEMA, CARDIOVASCULAR DYSFUNCTION | CORTECH, INC. (US) | 1997-12-23 | — | — | US | disclosed |
| EP-0783318-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO. INC. (US) | 1997-07-16 | — | — | EP | disclosed |
| WO-1997024343-A1 | PHENYL THIAZOLE DERIVATIVES WITH ANTI HERPES VIRUS PROPERTIES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1997-07-10 | — | — | WO | disclosed |
| US-5585359-A | LACK OF THIOL MOIETY PREVENTS THIOL-DEPENDENT CHEMICAL REACTIONS AND REDUCES SYSTEMIC TOXICITY | MERCK & CO., INC. (US) | 1996-12-17 | — | — | US | disclosed |
| US-5527882-A | BRADYKININ | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-06-18 | — | — | US | disclosed |
| WO-1996009836-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11389464-B2 | Arginase inhibitors as therapeutics | ARG1, ARG2, PRMT1 | HDAC3 324/4885HDAC1 108/4885HDAC2 101/4885 |
| US-20240189486-A1 | ANTIMICROBIAL CATIONIC PEPTOID AND N-SUBTITUTED PEPTIDIC COPOLYMERS, PREPARATION AND USES THEREOF | NGLY1, VIP, FPR3 | HDAC3 4231/4885HDAC1 4563/4885HDAC2 4296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.